-
UPDATE: Oppenheimer Initiates Coverage on Karyopharm Therapeutics on Novel Mechanism with Broad Applicability in Oncology
Monday, December 2, 2013 - 9:31am | 155Read More...In a report published Monday, Oppenheimer analyst David Ferreiro initiated coverage on Karyopharm Therapeutics (NASDAQ: KPTI) with an Outperform rating and $23.00 price target. In the report, Oppenheimer noted, “Karyopharm Therapeutics (KPTI) is focused on the development of novel small-molecule...
-
Ariad Pharmaceuticals Able to Continue Its EU Iclusig Sales
Friday, November 22, 2013 - 5:05pm | 328Read More...Shares of Ariad Pharmaceuticals (NASDAQ: ARIA) surged Friday, after the company revealed advisors to European Union regulators believe the company's Iclusig cancer drug should stay on the European market. Iclusig is used to treat two rare types of leukemia. Iclusig is Ariad's only product and...
-
UPDATE: Oppenheimer Raises PT on Regeneron Pharmaceuticals Following Results of VIVID & VISTA Studies
Monday, September 30, 2013 - 12:19pm | 145Read More...In a report published Monday, Oppenheimer analyst David Ferreiro reiterated an Outperform rating on Regeneron Pharmaceuticals (NASDAQ: REGN), and raised the price target from $300.00 to $310.00. In the report, Oppenheimer noted, “Following up on its announcement of top-line results in July, REGN...
-
UPDATE: Oppenheimer Upgrades Ariad Pharmaceuticals on Revised Outlook Following Recent Updates
Monday, September 30, 2013 - 8:59am | 150Read More...In a report published Monday, Oppenheimer analyst David Ferreiro upgraded the rating on Ariad Pharmaceuticals (NASDAQ: ARIA) from Perform to Outperform, and raised the price target from $23.00 to $24.00. In the report, Oppenheimer noted, “Following ARIA's recent updates at ESMO, we revised our...
-
UPDATE: Oppenheimer Raised PT on Verastem Following Analyst Day
Friday, July 12, 2013 - 8:31am | 176Read More...In a report published Friday, Oppenheimer analyst David Ferreiro reiterated an Outperform rating on Verastem (NASDAQ: VSTM), but lowered the price target from $16.00 to $18.00. In the report, Oppenheimer noted, “VSTM provided a more granular view of the cancer stem cell (CSC) platform/pipeline...
-
UPDATE: Oppenheimer Initiates Kamada at Outperform on Pioneering Inhaled Delivery with AAT Treatment
Tuesday, June 25, 2013 - 9:35am | 130Read More...In a report published on Tuesday, Oppenheimer analyst David Ferreiro initiated coverage on Kamada (NASDAQ: KMDA) with an Outperform rating and a price target of $14. In the report, Oppenheimer stated, "KMDA's key commercial product is Glassia, an intravenous treatment for alpha-1 antitrypsin (...
-
UPDATE: Oppenheimer Initiates Coverage on Neurocrine Biosciences on Potential Elagolix Success
Tuesday, June 18, 2013 - 5:40pm | 92Read More...In a report published on Tuesday, Oppenheimer analyst David Ferreiro initiated coverage on Neurocrine Biosciences (NASDAQ: NBIX) with a rating of Outperform and a price target of $16. In the report, Oppenheimer stated, "in the ph.III endometriosis results (1H14) and the ph.IIb fibroids results (...
-
Oppenheimer Reiterates Outperform Rating on Gilead Sciences Following Initial Idelalisib Ph.II Results
Monday, June 17, 2013 - 11:15am | 162Read More...In a report published Monday, Oppenheimer analyst David Ferreiro reiterated an Outperform rating and $61.00 price target on Gilead Sciences (NASDAQ: GILD). In the report, Oppenheimer noted, “GILD reported initial ph.II results evaluating idelalisib (PI3K inhibitor) monotherapy in refractory...
-
UPDATE: Oppenheimer Downgrades Rigel Pharmaceuticals on Disappointing Ph.III OKSIRA-2/3 Studies
Tuesday, June 4, 2013 - 1:19pm | 137Read More...In a report published on Tuesday, Oppenheimer analyst David Ferreiro downgraded Rigel Pharmaceuticals (NASDAQ: RIGL) from Outperform to Perform and removed the price target of $10. In the report, Oppenheimer noted, "As in the prior OKSIRA-1 results (methotrexate-failures), fostamatinib showed...
